Borm J J, Krediet R, Sturk A, ten Cate J W
Haemostasis. 1986;16 Suppl 2:59-68. doi: 10.1159/000215582.
Ten patients on chronic intermittent hemodialysis treatment received either unfractionated heparin or low molecular weight (LMW) heparin K 2165 in a single-blinded randomized cross-over study to assess: effects on hemostasis and ex vivo platelet functions, and effectiveness, i.e. prevention of fibrin formation in the extracorporeal circuit. The 20 dialysis treatments were without untoward side effects, for both drugs used. The variation in the plasma anti-Xa activities was significantly less during K 2165 treatment than during heparinization. No differences between the drugs were observed regarding the Ivy bleeding time, platelet count and platelet aggregation (spontaneous, and induced by ADP and collagen). Plasma platelet factor 4 levels did not increase under K 2165 to such an extent as under heparin. Both drugs did not influence the plasma levels of beta-thromboglobulin, thromboxane B2 and platelet serotonin content. K 2165 did not affect platelet adhesion to collagen, in contrast to heparin which substantially inhibited platelet adhesion. Under both treatments, 4 minor clots were observed in 4 artificial kidneys, despite plasma anti-Xa levels in between 0.19 and 0.46 U/ml. K 2165 may therefore be considered as effective an anticoagulant as heparin, with less effects on ex vivo platelet functions.
在一项单盲随机交叉研究中，10名接受慢性间歇性血液透析治疗的患者分别接受了普通肝素或低分子量（LMW）肝素K 2165治疗，以评估：对止血和体外血小板功能的影响，以及有效性，即预防体外循环中纤维蛋白形成。两种药物进行的20次透析治疗均未出现不良反应。与肝素化期间相比，K 2165治疗期间血浆抗Xa活性的变化明显更小。在伊维出血时间、血小板计数和血小板聚集（自发性、由ADP和胶原诱导）方面，未观察到两种药物之间存在差异。在K 2165治疗下，血浆血小板因子4水平升高的程度不如肝素治疗下那么高。两种药物均未影响血浆β-血小板球蛋白、血栓素B2水平和血小板血清素含量。与显著抑制血小板黏附的肝素不同，K 2165不影响血小板对胶原的黏附。尽管血浆抗Xa水平在0.19至0.46 U/ml之间，但在两种治疗下，4个人工肾中均观察到4个小血栓。因此，K 2165可被认为是一种与肝素同样有效的抗凝剂，对体外血小板功能的影响较小。
